Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Iconic iceberg turns blue, on verge of totally disintegrating, NASA says - 2Arctic sea ice just dropped to an alarming new low
- 3The Oscars are moving from ABC to YouTube starting in 2029
- 4Italian court approves extradition to Germany of Ukrainian suspect in Nord Stream pipeline blast
- 5The Response to Self-improvement: Embracing a Development Outlook
- Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- Popular Home Rug Series For You
- Figure out how to Perceive Warnings while Looking for an Auto Collision Lawyer
- The 15 Most Motivating TED Discusses All Time
- Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- 5 Home EV Chargers for Proficient and Solid Charging
- Journey Travel Objections for Your Next Experience
- Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- Manual for Tracking down the Mysterious Cascades in China
